• 2025.06.13 RESEARCHES Notice of Amendment to Terms and Conditions of the Usage License for a Healthy Human-derived iPS Cell Line for Research (CFiS Series)
• 2025.03.26 RESEARCHES iPS Cell Stock Collaboration Agreement Signing Between Mayo Clinic and CiRA Foundation
• 2025.01.14 RESEARCHES Notice on our iPS cell stock “QHJI01s04”
• 2024.03.19 RESEARCHES Terumo Blood and Cell Technologies partners with CiRA Foundation to develop automated iPS cell manufacturing
• 2024.02.22 RESEARCHES Registration of iPS cell stock (QHJI strain) for clinical use as a U.S. Drug Master File
• 2024.01.18 RESEARCHES CiRA_F and CIRM Sign Agreement for Widespread Use of iPS Cell Stock
• 2023.12.26 RESEARCHES Start of Investigator-Initiated Clinical Study of iPS Cell-Derived Dopaminergic Progenitor Cells for Parkinson's Disease in the United States
• 2023.06.14 RESEARCHES Provision of HLA Genome-edited iPS Cell Stock for Clinical Use
• 2023.04.11 RESEARCHES CiRA Foundation Signed Letter of Intent with Transformative Cell Processing Company
• 2023.04.05 RESEARCHES Provision of a New iPS Cell Line for Clinical Use
• 2023.03.02 RESEARCHES Knowledge Palette and CiRA Foundation Executed a Collaborative Research Contract to Evaluate and Improve Quality of iPS Cells
• 2022.12.27 RESEARCHES Toshiba and the CiRA Foundation Begin Joint Research on Methods for Manufacturing iPS Cells Using Liposome technology
• 2022.12.20 RESEARCHES Thyas Enters into Joint Research Agreement and Exclusive License for Data and Patents of Clinical Manufacturing of iPSC-Derived CAR-NK Cells
• 2022.11.17 RESEARCHES Update on the iPS Cell Stock at the CiRA Foundation
• 2022.06.30 RESEARCHES Update on Overseas Regulatory Review
• 2022.06.13 RESEARCHES Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application
• 2022.03.15 RESEARCHES A Bridge from Japan to Korea:
  CiRA Foundation's First Provision of Clinical-Grade iPS Cell Stock Overseas
• 2021.08.05 RESEARCHES Free provision of iPS cells made from 6 COVID-19 convalescent patients
• 2021.06.01 RESEARCHES First shipment of the iPS cell stock to an overseas partner
• 2021.05.19 RESEARCHES Provision of HLA-homozygous iPS cellｓ to Novo Nordisk
• 2021.05.18 RESEARCHES Platelets derived using the CiRA Foundation iPS Cell Stock enter an industry-led clinical trial
• 2021.05.10 RESEARCHES CiRA Foundation's First International Provision of HLA-homozygous iPS cell stock to CHA University in Korea
• 2021.03.26 RESEARCHES HLA-genome-edited iPS cell production contracted by Vision Care Inc.
• 2021.03.25 RESEARCHES CiRA Foundation is now accepting applications for the free provision of iPS cells made from COVID-19 convalescent patients
• 2021.02.01 RESEARCHES Basic agreement with Thyas for the manufacturing of iPS cell-derived T cells - Joint research on the utilization of my iPSR has also begun
• 2020.06.24 RESEARCHES Calls for "my iPS" collaborative research
• 2020.06.22 RESEARCHES CiRA Foundation has been entrusted by Megakaryon to manufacture iPS cell-derived platelets for a clinical trial
• 2020.05.15 RESEARCHES CiRA Foundation and Taiwan National Chiao Tung University signed a MOU on education and scientific research
• 2020.05.12 RESEARCHES CiRA Foundation and the Cell and Gene Therapy Catapult set to launch new stem cell collaborative research